About ALNA

Allena Pharmaceuticals, Inc. is a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ALNA is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
VTHR Vanguard Russell 3000 ETF 459.1 M 4.591E+08 2,932 2932 0.0% 0 32 32
VTI Vanguard Total Stock Market ETF 116.3 B 1.163E+11 3,604 3604 0.0% 0 164 K 164032
VTWG Vanguard Russell 2000 Growth ETF 304.1 M 3.041E+08 1,351 1351 0.0% 0 2 2
VXF Vanguard Extended Market ETF 7.1 B 7.1E+09 3,265 3265 0.0% 1E-05 70 K 70077
ITOT iShares Core S&P Total U.S. Stock Market ETF 21.5 B 2.14655E+10 3,566 3566 0.0% 0 271 K 271009
IWC iShares Microcap ETF 860.2 M 8.60207E+08 1,398 1398 0.02% 0.0002 149 K 148544